BriaCell Therapeutics Corp.

Contributing Author

Recent Articles by BriaCell Therapeutics Corp.

13 hours	BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ at SITC 2025 BCTX +15.06% GlobeNewswire
Nov-04	BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ in Breast and Prostate Cancer Models BCTX GlobeNewswire
Oct-22	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer BCTX GlobeNewswire
Oct-21	BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study BCTX GlobeNewswire
Oct-21	BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer BCTX GlobeNewswire
Oct-20	BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025 BCTX GlobeNewswire
Oct-13	BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025 BCTX GlobeNewswire
Oct-03	BriaCell to Present Bria-OTS+ Preclinical Data at SITC 2025 Annual Meeting BCTX GlobeNewswire
Aug-26	BriaCell's Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal BCTX GlobeNewswire
Aug-25	BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate Cancer BCTX GlobeNewswire
Aug-21	BriaCell Announces Proposed Effective Date of Share Consolidation BCTX GlobeNewswire
Aug-13	BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer BCTX GlobeNewswire
Aug-05	BriaCell Announces Proposed Effective Date of Share Consolidation BCTX GlobeNewswire
Jul-31	BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study BCTX GlobeNewswire
Jul-30	BriaCell Awarded New Zealand Patent for its Whole Cell Technology BCTX GlobeNewswire
Jul-25	BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025 BCTX GlobeNewswire
Jul-16	BriaCell Therapeutics Announces Closing of $15 million Public Offering BCTX GlobeNewswire
Jul-15	BriaCell Therapeutics Announces Pricing of $15 million Public Offering BCTX GlobeNewswire
Jul-15	BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer BCTX GlobeNewswire
Jul-11	BriaCell's Bria-IMT Demonstrates Survival Advantage over Trodelvy and Control Group in Metastatic Breast Cancer BCTX GlobeNewswire
Jul-10	BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient BCTX GlobeNewswire
Jul-09	BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS Metastatic Breast Cancer Study BCTX GlobeNewswire
Jul-08	BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer BCTX GlobeNewswire
Jul-02	BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven BCTX GlobeNewswire
Jun-24	BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer BCTX GlobeNewswire
Jun-04	BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 BCTX GlobeNewswire
Jun-02	BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 BCTX GlobeNewswire
May-27	BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor BCTX GlobeNewswire
May-23	BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 BCTX GlobeNewswire
May-20	BriaCell CEO Letter to Shareholders BCTX GlobeNewswire

BriaCell Therapeutics Corp.

Recent Articles by BriaCell Therapeutics Corp.

Upgrade your FINVIZ experience